Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET-Negative, HRAS-, and NF1-Mutated Metastatic Medullary Thyroid Carcinoma
Background: Selpercatinib is approved for RET-mutated medullary thyroid carcinoma (MTC); its activity in tumors without detectable RET alterations is uncertain. Patient Findings: A 50-year-old woman developed rapidly progressive MTC (Ki-67 = 30%) with extensive liver and bone metastases. Because of severe symptomatic p...